Last reviewed · How we verify
SAR439459
At a glance
| Generic name | SAR439459 |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI) (PHASE1)
- Isatuximab in Combination With Novel Agents in RRMM - Master Protocol (PHASE1, PHASE2)
- A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors (PHASE1)
- SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SAR439459 CI brief — competitive landscape report
- SAR439459 updates RSS · CI watch RSS
- Sanofi portfolio CI